ACP Ranks Obesity Drug Options - Summary - MDSpire
Advertisement
ACP Ranks Obesity Drug Options
A living clinical guideline outlines a treatment hierarchy for selected pharmacologic therapies in patients with obesity and selected patients with overweight.
To provide guidance on pharmacologic treatment options for weight management in nonpregnant adult patients with obesity and selected patients with overweight and weight-related comorbidities.
Approach:
Guideline Development: Developed by the American College of Physicians (ACP) Clinical Guidelines Committee based on systematic reviews of pharmacologic treatments and using the Grading of Recommendations Assessment, Development, and Evaluation approach.
Evidence Review: Systematic review evaluated randomized controlled trials published in English through October 2025, focusing on various health outcomes related to obesity treatments.
Key Findings:
Semaglutide and tirzepatide are conditionally suggested as first-line treatments for nonpregnant patients with obesity.
Phentermine-topiramate is suggested as a second-line option, liraglutide as third-line, and naltrexone-bupropion as fourth-line treatment.
For patients with overweight and weight-related comorbidities, semaglutide and tirzepatide are also conditionally suggested as first-line treatments.
Evidence showed semaglutide reduced all-cause mortality and major adverse cardiovascular events compared to lifestyle modifications alone.
Tirzepatide improved weight loss and health-related quality of life compared to semaglutide but showed low-certainty evidence for all-cause mortality and major adverse cardiovascular events.
Interpretation:
The guideline discusses the need for clinicians to consider various factors such as benefits, harms, costs, and individual preferences when discussing treatment options with patients.
Limitations:
Evidence was largely based on studies enrolling patients with class 2 obesity.
No studies used waist or hip circumference as primary inclusion criteria.
Conclusion:
The ACP plans to maintain the guideline as a living document, updating it as new evidence becomes available.
Shear wave velocity measurements in the basal anteroseptal and right ventricular walls differed between transthyretin and light chain cardiac amyloidosis when conventional echocardiographic parameters did not.
The procedure was performed under a HOPE Act research protocol at an NYU Langone Health center the institution said is among the limited number of US transplant centers equipped and approved to perform HOPE lung transplants.
